Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSV cps2
- Development stage
- Unknown
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intranasal (based On Typical Administration Route For Live Attenuated Rsv Vaccines)
01
Overview
RSV cps2 is a recombinant live-attenuated vaccine candidate developed for the prevention of respiratory syncytial virus (RSV) infection, primarily in infants and young children. It was engineered to improve genetic stability and attenuation compared to earlier candidates by incorporating multiple independently attenuating mutations, including temperature-sensitive and cold-passaged elements as well as a deletion in the SH gene. These modifications reduce viral replication at higher temperatures (such as those found in the lower respiratory tract), enhancing safety while maintaining immunogenicity. The vaccine is designed to stimulate an immune response against RSV without causing disease, thereby providing protection against subsequent natural infection[5][7][2]. Clinical studies have shown that it is well-tolerated and immunogenic in seronegative infants and children[2][5].
- Other names
- RSVcps2RSVcps-2RSVcps 2
02
Targets
RSV (Respiratory syncytial virus)
Beyond the preview
Go deeper on RSV cps2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSV cps2.